Analysis of health, neurodevelopmental, and school performance outcomes in a pilot study of term and near-term infants with respiratory failure due to pneumonia or meconium aspiration treated with surfactant.
Newborns with respiratory failure are at increased risk for adverse neurodevelopmental outcome, which may include sensorineural hearing loss, 1 cognitive and motor delays, 2 behavioral problems, and school failure. 3, 4 Long-term outcome studies in this high-risk group are more limited in scope and number than are follow-up studies of premature infants. Studies are complicated by the variable etiologies and pathophysiological mechanisms that are present in near-term infants with respiratory failure. For example, patients with persistent pulmonary hypertension associated with asphyxia would likely be at higher neurodevelopmental risk than patients with pneumonia who had similar impairment of gas exchange. Small numbers of patients in each diagnostic group have limited the power of outcome studies in term infants with respiratory failure. This is particularly true because of the increasing number of new treatments introduced in recent years, including surfactant, high-frequency ventilation, nitric oxide, and extracorporeal membrane oxygenation (ECMO). Studies have also been limited by having enrollees lost to follow-up, which may bias results.
The present report is a follow-up evaluation of our original pilot study of surfactant treatment in term and near-term infants with respiratory failure, which we began in 1988. We used calf lung surfactant extract, identical with Infasurf (Forest Pharmaceuticals, St. Louis, MO) calfactant, as a treatment for severe respiratory failure. We reported the short-term outcomes of all 14 enrolled newborns (7 infants with pneumonia and 7 infants with meconium aspiration syndrome) in 1991. 5 We now report the overall health, neurodevelopmental, cognitive, and behavioral outcomes at a mean age of 7.2 Ϯ 0.8 years.
MATERIALS AND METHODS
Newborns with pneumonia, meconium aspiration syndrome, sepsis, or asphyxia, but without congenital heart or lung abnormalities were eligible for entry if they required mechanical ventilation at a mean airway pressure of Ն7 cm H 2 O, required FIO 2 of Ն0.5, and were Յ3 days of age at enrollment. Four patients initially enrolled were excluded from subsequent surfactant treatment and analysis because of congenital abnormalities (diaphragmatic hernia, n ϭ 2; pulmonary hypoplasia, n ϭ 1; interrupted aortic arch, n ϭ 1). The oxygenation index at entry was 26.2 Ϯ 3.1 (mean Ϯ SD). The remaining 14 patients that were enrolled survived, and none required ECMO; they were discharged and were evaluated at school age in the Strong Children's Medical Center Continuing Care Clinic. The baseline characteristics of enrollees are noted in Table 1 .
Procedure
Hospital records were reviewed. Health survey questionnaires and medical records were used to evaluate general health, with an emphasis on respiratory and sensorineural outcomes. Parents, teachers, and
physicians completed a standard questionnaire. Socioeconomic status was determined at the time of the evaluation using the Hollingshead scale, which uses the average score of two parents, computed using a scale ranking the highest formal educational level attained combined with an occupational rating. 6 Scores range from 8 to 66. A neurologist and neuropsychologist evaluated the children. The neurologic assessment consisted of an evaluation of mental status, activity, cranial nerves, motor system (gait, tone, strength, deep tendon reflexes, and coordination), cerebellar system, and sensation. The neuropsychologist determined cognitive abilities using the Wechsler Intelligence Scale for Children III (WISC-III) and the Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R). School administered intelligence quotient (IQ) testing was used if the child did not live locally or if the parent was unable to bring the child for an evaluation. Teachers rated each child on school performance and placement. Academic performance was rated on a scale of 1 through 5 according to the following criteria: 1, far below average; 2, below average; 3, average; 4, above average; 5, far above average. Teachers also identified special education classification if applicable and types of additional services child was receiving (i.e., occupational therapy, physical therapy, etc.). The functional independence measure for children (WeeFIM) was administered by developmental psychologists. 7 This assessment is based on 18 functional independence milestones achieved at certain ages, with scores on each item ranging from 1 (dependent) to 7 (independent). The maximum score indicating full independence at an age of 92 to 95 months is 126. Conners behavioral surveys were completed by parents and teachers of each study subject. 8 
RESULTS
The neurodevelopmental, behavioral, and school performance outcomes are summarized in Table 2 . Of the 14 patients evaluated, only one was rehospitalized for a respiratory complaint, pneumonia. Two were receiving bronchodilators for reactive airways disease. Three were reported to have had episodes of wheezing. None were rehospitalized for asthma or croup.
One subject had unilateral sensorineural hearing loss. None had visual impairments. One had a speech impairment. Only one patient had a full-scale IQ (FSIQ) below normal, at 65. This patient also had a Hollingshead score of 11. The neurologic functional score for the group was 9.2 Ϯ 1.2, with only one patient scoring Ͻ8.
Behavioral evaluation using the Conners surveys completed by the parents and teachers demonstrated abnormalities in four patients (two reported by parents and two reported by teachers). The patient who had the FSIQ of 65 was reported by the parent to have difficulties in all five subscales, and was being treated with methylphenidate for hyperactivity. The second child was reported by the parent to have difficulties with impulsivity and hyperactivity. A third patient was reported by a teacher to have difficulties with conduct and hyperactivity, but was reported normal by the parent. A fourth child was reported by the teacher to be impulsive, but was reported normal by the parent. One patient was reported to be normal by the parent, but the parent did not want the school contacted, hence the absence of the teacher completed survey. A total of 13 of 14 subjects had academic performance ratings. All but one of these had ratings of Ն3. Two children received speech therapy, and one of those children was enrolled in remedial reading.
DISCUSSION
The findings reported in this study, necessarily limited by its small size, suggest that near-term and term newborns with moderately severe respiratory failure treated with surfactant can, in general, be expected to recover completely, avoid long-term pulmonary morbidity, and have normal neurodevelopmental outcome and school performance.
Children with severe respiratory failure are at significant risk for abnormal neurodevelopmental outcome, with risks for major disabilities as high as 20%, and school failure as high as 40%. Reported problems include sensorineural hearing loss, 1 mental retardation, 9 behavioral problems, hyperactivity, and high risk for school failure. 4, 10 Most of the larger studies of sick term and near-term infants have evaluated newborns treated with ECMO or who qualified to receive ECMO, socalled "near miss ECMO." In contrast, only 1 of the 14 patients in our pilot study showed significant cognitive impairment or abnormal school performance. We found little variation in the FSIQ in this group (101 Ϯ 13). This contrasts with the reports by Glass and colleagues, 3, 4, 11 who reported significant variation in FSIQ in schoolaged children who received ECMO (96 Ϯ 20), or who were near-miss ECMO candidates (91 Ϯ 22). In addition to wide variations in FSIQ, 46% to 56% of ECMO 4 and near-miss ECMO 3 patients were judged "at risk" for school failure, which contrasts sharply with the performance in our group. Four of our patients were reported to have hyperactivity or impulsivity, which is consistent with behavioral problems reported in other high-risk groups.
Comparison of our data with other reports of full-term infants after severe respiratory failure is problematic. To our knowledge, no long-term follow-up reports for the published larger, controlled trials 12, 13 of surfactant in term and near-term infants have been presented. These groups would be expected to be more comparable with our own, because the severity of illness measured by the oxygenation index at study entry was comparable (25 Ϯ 6 vs 26.2 Ϯ 3.1). 13 The largest and most systematic reports of neurodevelopmental results in term infants with severe respiratory failure evaluated ECMOtreated newborns.
2,4,11,14 ECMO-treated and near-miss ECMO groups would be expected to be at greater neurodevelopmental risk. The severity of illness reflected in the oxygenation index in these patients was certainly higher than in our group, as measured at the time they qualified for ECMO, generally when they were judged to have an 80% probability of mortality without ECMO. Some of the ECMO or nearmiss ECMO patients evaluated in previous reports undoubtedly received surfactant before ECMO. Patients who received ECMO may have received high-frequency ventilation, and more recently, nitric oxide. Therefore, the patients who received ECMO would have failed these and other medical management approaches. They would have had delays in restoration of normal oxygenation (mean age at ECMO ϭ 61 Ϯ 40 hours) 4 and would be expected to have more severe underlying impairments of cardiopulmonary function, and hence be at increased neurodevelopmental risk.
Larger controlled studies of surfactant versus placebo in nearterm and term infants such as those reported by Findlay et al 12 and Lotze et al 13 should be able to provide a clearer picture of the longterm health, neurodevelopmental, and scholastic outcome of children treated with surfactant at term for respiratory failure, once their subjects reach school age.
